Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- What is Induction Therapy for Myeloma?
What is Induction Therapy for Myeloma?
What is induction therapy for myeloma? The FDA approved standard-of-care chemo cocktail is velcade, bortezomib, daratumumab and dexamethasone or DVR-d.
The definition of induction therapy is:
“the initial phase of treatment for multiple myeloma, where a combination of drugs is administered to rapidly reduce the number of myeloma cells in the bone marrow, aiming to achieve a deep remission and prepare the patient for further treatment like a stem cell transplant, if eligible; essentially, it’s the first line of treatment to quickly control the disease with a combination of targeted therapies, chemotherapy, and corticosteroids.”
I’m writing this post for two reasons. First, newly diagnosed myeloma (NDMM) are scared, depressed, angry, etc. and I think they will benefit from understanding what their first line of treatment will be.
Secondly, I think NDMM patients can be encouraged by the improvements oncology has made with induction therapy over the past 30-40 years.
According to research induction therapy of:
- Induction therapy of melphalan/predisone were associated with a progression-free survival of 18 months to 2 years and an overall survival of 4 to 5 years.
- Induction therapy of vincristine, adriamycin and dexamethasone were associated with an overall survival of 36 months and
- Induction therapy of DVR-d is associated with progression-free survival of 84.3% at 4 years and median survival rate is more than 6 years.
What in induction therapy for myeloma?
I am a long-term MM survivor. Conventional oncology does not learn about or speak to evidence-based non-conventional therapies such as nutrition, supplementation and lifestyle therapies. I believe these non-conventional therapies must be an important part of all MM patients regimens.
Email me at David.PeopleBeatingCancer@gmail.com with any questions you have about your MM, your symptoms, side effects, etc.
Thank you,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Induction Therapy for Newly Diagnosed Multiple Myeloma
“Practical Applications
•Triplet induction regimens are the standard of care for the majority of newly diagnosed patients with multiple myeloma, with doublets only restricted to frail, elderly patients.
•Goals of induction are to get quick disease cytoreduction, reversal of end organ damage, and improvement of performance status regardless of the transplant eligibility.
•Monoclonal antibody–based regimens are making their way to the frontline setting for both transplant-eligible and transplant-ineligible patients with MM…
For decades, low-dose melphalan and prednisone constituted the cornerstone of MM treatment.
However, complete responses (CRs) with this regimen were rare, and the median time to progression was less than 15 months.2,3 The advent of high doses of melphalan with autologous hematopoietic stem cell transplantation (AHSCT) was a major advance showing improved response rates, progression-free survival (PFS), and—in some trials—prolonged overall survival (OS) in patients with MM, and continues to be a cornerstone of treatment for eligible patients.4–8
Similarly, the adoption of the immunomodulatory drugs (i.e., thalidomide, lenalidomide, and pomalidomide)9–12 and the proteasome inhibitors (i.e., bortezomib, carfilzomib, and ixazomib)13–18 into management of newly diagnosed MM (NDMM) has improved outcomes and has led to their widespread incorporation into frontline regimens in both transplant eligible and ineligible patients.
Recent data suggest that a deeper remission, as evidenced by absence of minimal residual disease (MRD) at levels < 1 × 10−6, correlates with improved time to progression, PFS, and OS,19–22 suggesting that the goal of treatment for patients with NDMM should be to induce the deepest remission possible…
Induction therapy for myeloma Induction therapy for myeloma Induction therapy for myeloma